• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Crown Bioscience names Dr. Jean Pierre Wery as chief financial officer

Crown Bioscience names Dr. Jean Pierre Wery as chief financial officer

August 31, 2016
CenterWatch Staff

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced that President Dr. Jean Pierre Wery has moved into the role of chief executive officer.

In addition to Dr. Wery's recent nomination as CEO, Dr. Alex Wu, co-founder of CrownBio takes the role of president and chief strategy officer, while Eva Ho has been appointed chief financial officer.

"In 2016 CrownBio has experienced unprecedented growth with increasing demand for our Immuno-Oncology and Cardiovascular and Metabolic Disease services and models," said Wery. "As newly appointed CEO my objective is to foster the development of new products, cutting-edge technologies, and services for oncology and metabolic disease, while contemplating a possible expansion into new therapeutic areas."

To further demonstrate CrownBio's commitment to support its global growth, the Board of Directors has chosen Ms. Ho for the role of CFO. Ho brings years of experience in financial planning and analysis, having led the financial operations of well renowned global companies. Ho will take on Bing Zhu's previous role, who has now been appointed chief operating officer.

The consolidation of CrownBio's leadership team demonstrates the company's dedication to provide an experienced management team to drive forward the advancement of drug discovery worldwide.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing